Addressing Antibody-Drug Conjugate Development Challenges
Abzena’s Scientific Leader and Senior Vice President, Petra Dieterich Ph.D., features in a new article on Biocompare.
As part of the articles ‘Addressing Antibody-Drug Conjugate Development Challenges’ feature, Petra provided her thoughts on how ADC products still face existential issues like off-target toxicity, tumor heterogeneity, and unpredictable pharmacokinetics (PK).
“Tumor heterogeneity leading to treatment resistance also leads to different responses to treatment, which gives rise to ADC-resistant tumor types,” adds Petra Dieterich, Ph.D., Scientific Leader at Abzena.”
“Drug developers are investigating several alternative formats to address these shortcomings,” Dieterich says, “including dual payload ADCs, bispecific ADCs and proteolytically activated antibody prodrugs (probodies).”
Abstract
Combining cancer cell-seeking antibodies with tumor-killing drugs or radionuclides is an old idea whose current embodiment, antibody-drug conjugates (ADCs), results from several generations of improvements leading from murine or chimeric antibodies unstably linked to poorly characterized payloads, to fully humanized antibodies, site-specific conjugation, and precisely calculated drug-antibody combinations…
Read the full article on Biocompare.
The post Addressing Antibody-Drug Conjugate Development Challenges appeared first on Abzena.